摘要
目的探讨不同类型肝病患者凝血四项和D二聚体(D-D)、纤维蛋白/纤维蛋白原降解产物(FDP)水平的变化及临床意义。方法选用法国STA-R(Evolution)全自动血凝仪检测89例肝病患者和30例正常人群(对照组)的凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、纤维蛋白原(Fbg)、凝血酶时间(TT)、D-D和FDP水平。结果不同类型肝病患者PT、aPTT、TT较对照组均明显延长(P<0.05);Fbg含量均低于对照组(P<0.05);肝硬化、肝硬化失代偿及肝功能衰竭患者D-D、FDP活性明显高于对照组(P<0.05),而慢性肝炎组与对照组相比差异无统计学意义,各型肝病患者D-二聚体、Fbg水平呈现肝硬化失代偿或肝功能衰竭>肝硬化>慢性肝炎。结论凝血四项和D-D、FDP水平的联合检测可评估肝病患者的体内出凝血的状况,并根据Fbg、D-D和FDP综合判断是否继发纤溶亢进,可以为临床肝脏疾病的诊断及鉴别诊断、治疗、动态观察以及判断预后提供重要依据。.
Objective To study the clinical value of detection four blood coagulation tests, D-dimer and FDP on the various types of liver disease. Methods Test the value of four blood coagulation tests （ PT, a PTT,Fbg,TT） ,D-dimer and FDP on 30 healthy volunteers and 89 patients who had been diagnosed to liver disease by STA-R（Evolution） auto blood coagulation analyzer. Results Compared with the healthy group, the values of PT ,a PTT,Fbg of different kinds of patients with liver disease significantly prolonged （P 〈 0. 05 ） , TT significantly decreased （ P 〈 0. 05 ） ; the level of D- dimer and FDP in cirrhosis group, Decompensated liver cir- rhosis or Hepatic failure were significantly prolonged （ P 〈 0. 05 ） ; In the chronic hepatitis group, D- dimer and FDP had no difference （ P 〉 0.05 ）. The level of D- dimer and FDP in patients with liver diease present decom- pensated liver cirrhosis or hepatic failure 〉 cirrhosis group 〉 chronic hepatitis group. Conclusion Analysis of the four blood coagulation tests, D-dimer and FDP in patients with liver disease can objectively evaluate the coagulation status of patients with liver disease, and according to the Fbg, D-dimer, FDP, comprehensively judge whether a secondary fibrinolytic hyperfunction, they can provide important evidences for the diagnosis,treatment.
出处
《血栓与止血学》
2016年第3期283-285,共3页
Chinese Journal of Thrombosis and Hemostasis
